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Abstract

Objective
The objective of this systematic review is to determine whether or not antibiotic treatment is safe
and effective in healing tympanic membrane (TM) perforation in Aboriginal children diagnosed
with chronic suppurative otitis media and otitis media with effusion less than 16 years of age.
Study Design
The author conducted a review of three studies published in English in peer-review journals. One
of these studies was published in 2003 and the other two in 2008.
Data Sources
All three studies were conducted as either double-blinded or assessor-blinded randomized
controlled trials. The author found the articles through the Ovid and Cochrane databases.
Outcomes Measured
The outcomes measured for each of the three trials was the TM perforation size or healing at the
end of the study treatment with either topical framycetin (0.5%), gramicidin, and dexamethasone
(FGD), topical ciprofloxacin or long-term systemic amoxicillin.
Results
One study, which compared topical FGD to topical ciprofloxacin and assessed TM perforation at
the end of therapy noted 23% of patients treated with FGD and 26% of patients treated with
ciprofloxacin as having a one or two step decrement in TM perforation at the end of treatment.
The second study comparing topical FGD to topical ciprofloxacin noted 100% of patients treated
with FGD and 98% of patients treated with ciprofloxacin having failure to heal TM perforation
at the end of therapy. The study looking at long-term systemic amoxicillin versus placebo for
TM perforation healing noted 27% of placebo patients and 12% of amoxicillin patients with
remaining TM perforation at the end of the trial.
Conclusions
In this systematic review neither topical FGD nor topical ciprofloxacin significantly changed TM
perforation size after treatment. Significant results, however, are noted in TM perforation
prevention with use of long-term systemic amoxicillin.
Key Words
Antibiotic treatment, amoxicillin, framycetin-gramicidin-dexamethasone (FGD), ciprofloxacin,
otitis media, Aboriginal children
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Introduction
Otitis media (OM) is an infection seen in patients of all ages, but most commonly seen in
the pediatric population. Current treatment for otitis media with effusion (OME) and chronic
suppurative otitis (CSOM) may not be effective enough to prevent complications in high-risk
populations, such as those of low socioeconomic status and those who are medically
underserved, underinsured or uninsured. This paper evaluates three clinical randomized
controlled trials on the prevention and treatment of tympanic membrane perforation. Two trials
compare the use of topical ciprofloxacin and a topical aminoglycoside containing framycetin
(0.5%), gramicidin, and dexamethasone (FGD) in Aboriginal children with CSOM while the
third looks at the long-term use of systemic amoxicillin in Aboriginal children with OME.
The topic of effective treatment for otitis media is important to Physician Assistants,
especially to those working in the specialties of family medicine, primary care or pediatrics.
Acute otitis media is the most common reason that children see a clinician with 30 million
pediatric physician visits each year. Clinicians with exposure to the pediatric population must be
knowledgeable in the treatment of OM6. In addition, those Physician Assistants working with the
“high-risk” populations described above must be aware that certain complications such as CSOM
or progression of AOM to tympanic membrane (TM) perforation are more common in these
populations. Additional risk factors of OM include children in daycare, those with multiple
siblings, exposure to cigarette smoke in the home, Down’s syndrome, pacifier use or formula
feeding6. In 1995 it was estimated that 2.95 billion dollars were spent on pediatric OM office
visits indicating the great deal of resources used for diagnosis of OM and the importance of
effective treatment8.
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Otitis media in an infection of the middle ear associated with effusion or otorrhea and can
progress to a chronic suppurative state if left untreated or if treated ineffectively. This infection
develops from respiratory tract inflammation leading to eustachian tube dysfunction and
development of transudate in the middle ear. Colonization and subsequent infection of the
transudate with viral or bacterial pathogens in the middle ear lead to acute or chronic otitis
media. Untreated acute OM can progress to TM perforation, CSOM and childhood hearing loss,
which have adverse effects on child development7. This review is primarily concerned with the
antibiotic effect in healing TM perforations because of the detrimental progression to childhood
hearing loss and developmental delay.
Currently the first line treatment for OM is systemic amoxicillin, 90 mg/kg/d up to 4 g/d
for five days in children older than two years and for 10 days in those less than two years old.
OM refractory to amoxicillin should be treated with systemic augmentin ES-600, 90 mg/kg/d.
OM with effusion persisting for more than four months is treated with ventilating tubes3. The
treatment for CSOM in the US is a topical fluoroquinolone while in Australia the preferred
treatment for CSOM is topical FGD, which is more effective than systemic antibiotic in treating
otorrhea seen in CSOM2. The dilemma and reason for this systematic review is two-fold. One,
the first-line therapy for acute OM is amoxicillin for five to 10 days but no studies have shown
whether long-term antibiotic treatment is safe and effective in high-risk populations with
persistent OM4. Second, the current first-line treatment for CSOM in Australia is topical FGD
despite the known ototoxicity of aminoglycosides. Topical ciprofloxacin has potential as a
treatment alternative to FGD and some studies show it is more effective in improving the
otorrhea of CSOM. The safety and efficacy of topical ciprofloxacin in treatment of CSOM in
Aboriginal children is unknown2,5.
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Objective
The objective of this systematic review is to determine whether or not antibiotic
treatment is safe and effective in healing tympanic membrane (TM) perforation in Aboriginal
children diagnosed with CSOM and OME less than 16 years of age.
Methods
A strict criterion was used to select the participants of the study. The population included
Aboriginal children less than 16 years of age with OME and CSOM. Two of the studies included
children from Aboriginal communities of northern Australia while the third study included three
remote Aboriginal communities in various regions of Australia2,4,5. The interventions being
studied are topical FGD, topical ciprofloxacin and long-term systemic amoxicillin for treatment
of TM perforation. All three studies were randomized controlled trials (RCT). In two of the
RCTs the treatment groups received ciprofloxacin and the placebo group received FGD. In the
third RCT the treatment group received systemic amoxicillin and the placebo group received no
treatment. The outcome measured was the size and healing of TM perforation at the end of
treatment, which qualifies as disease-oriented evidence (DOE) not patient oriented evidence that
matters (POEM)2,4,5. Had the investigators added a preventative element to their study such as
limiting OM risk factors such as smoking in the home or advising against activities that might
worsen TM perforation such as swimming then the outcome would have been one that the study
participants were actively involved in changing thus making it a POEM.
The author of this review conducted the data searches on the Ovid and Cochrane database
using the keywords “otitis media”, “aboriginal children” and “antibiotic treatment” from 1996 to
the present. All three articles chosen for the systematic review were written in English and were
published in peer-review journal articles. Articles included in the review were any RCT that
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studied the use of antibiotic therapy in Aboriginal children with some form of OM less than 16
years of age. Articles excluded from the study were those that were two variations of the same
study by the same author. The statistics reported in the three studies were CER (control event
rate), EER (experimental event rate), relative benefit increase (RBI), absolute benefit increase
(ABI), numbers needed to treat (NNT) and the confidence interval (CI). A p-value was reported
for the data specifically regarding TM perforation size or healing for only one of the three studies
2,4,5

. Table one details the specific studies reviewed including the type of study, the number and

age of patients, inclusion and exclusion criteria, and withdrawals and interventions.
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Table 1- Demographics and characteristics of included studies
Study

Type

#
Pts
147

Age
(yrs)
1-14
years

Couzos, S.,
Lea, T.,
Mueller, R.,
Murray, R.
et al. (2003)

Doubleblind,
randomized
controlled
trial

Leach, A. J.,
Morris, P.
S., Mathews,
J. D. et al.
(2008).

Double-blind
randomized
controlled
trial

103

< 12
mths

Leach, A.,
Wood, Y.,
Gadil, E. et
al. (2008)

Randomized
assessorblinded
controlled
trial

97

1-16
years

Inclusion
criteria
Aboriginal
children;
<15 years;
At least 2
weeks of
otorrhea;
TM
perforation

Exclusion
criteria
Febrile illness;
abx use in past 2
weeks;
ototopical med
allergy;
fluoroquinolone
allergy; need for
renal dialysis;
recent ear
surgery; in-situ
ear tube; hearing
loss; obstructed
middle ear;
pregnancy;
unlikely to be
resident at end
of study
Aboriginal
Prematurity
infant;
(<34 wks);
unilateral or chronic
bilateral OM infection
with
requiring
effusion
prophylactic
therapy;
craniofacial
abnormality;
immune
deficiency
syndrome
Aboriginal
Abx allergy;
children;
pregnancy;
chronic
breast-feeding;
perforation
tympanoplasty;
cholesteatoma;
severe medical
illness

W/
D
36

Interventions

9

Amoxicillin 50
mg/kg/day BID
vs. placebo x 24
weeks to
bilateral ears

8

Topical
Ciprofloxacin
vs. topical FGD,
4 drops 2x/day
to bilateral ears

Topical
ciprofloxacin vs.
topical FGD, 5
drops 2x/day to
bilateral ears x 9
days

Outcomes measured
In the Leach, Wood et al. study, the outcome measured was whether or not there was any
remaining TM perforation at end of therapy. TM perforations were measured through otoscopy,
video-otoscopy and drawings of the TM. The proportion of the TM perforation size to the TM
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surface area was determined. Two separate clinical assessors analyzed the video otosocopy and
the results were compiled. A third assessor resolved any differences in clinical assessment.
Couzos, Lea et al. looked for a one or two-step decrement in size of TM perforation at the
end of treatment. The authors did not give information regarding how they determined a “one”
versus “two-step” decrement in TM perforation size. Video otoscopy was used to assess the size
of the TM perforation as a proportion of the TM surface area. Aboriginal health workers
participating in the study and two otolaryngologists conducted the assessment of TM perforation.
Leach, Morris et al. studied whether or not there was any remaining TM perforation at
the end of therapy. Clinical records on the study participants were used to assess baseline
characteristics and pre-enrollment ear disease. The study participants were examined every two
weeks from the time of enrollment to the time of randomization. Participants were also assessed
monthly during the six month intervention period or until success was documented. An
Australian expert trained physicians and nurses to use video pneumatic otoscopy and
tympanometry to assess ear status, including TM perforation during and after the intervention.
Results
All three studies were conducted in the primary care outpatient setting with results being
presented as dichotomous data. The results of the studies by Leach, Wood et al. and Leach,
Morris et al. were examined using the “intention to treat analysis”. Patients enrolled in these two
studies were included in the analysis even if they withdrew from the study or were lost to followup. The most recent data on those patients who withdrew from the study or were lost to followup was analyzed or the patient was counted as a treatment failure. In the Couzos, Lea et al. study,
the children who were lost to follow-up were not included in the final data analysis so no
“intention to treat” analysis was performed.
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Two of the three studies included in this review were randomized, double-blind
controlled trials while one was a randomized, assessor-blinded controlled trial. In two of the
studies, the treatment groups received ciprofloxacin while the placebo received FGD. In the third
study the treatment group received long-term systemic amoxicillin and the placebo group
received no treatment. The Couzos, Lea et al. trial included children from one to 14 years with
two weeks of otorrhea and TM perforation, the Leach, Morris et al. study included children less
than 12 months old with bilateral OME and the Leach, Wood et al. study included children one
to 16 years old with chronic TM perforation.
Not all patients that were enrolled in each study completed the study. In the Leach,
Morris et al. study, 103 infants were randomized with two in the amoxicillin group and seven in
the placebo group discontinuing therapy. One infant in the amoxicillin and two in the placebo
group were withdrawn due to CSOM, while one infant in the amoxicillin group and three in the
placebo group were withdrawn by the parent for unspecified reasons. No patients in the
amoxicillin group and two patients in the placebo group were lost to follow-up. In the Couzos,
Lea et al. study 147 patients were randomly allocated while 36 patients did not complete the
study and were not included in the study analysis due to lack of sufficient data. Out of the 36
patients who did not complete the study, 18 were lost to follow-up, eight had incomplete followup, nine withdrew for unknown reasons and one withdrew because the patient’s otorrhea
improved. In the Leach, Wood et al. study, 50 patients in the treatment group and 47 in the
placebo group were randomized with five in the treatment group and three in the placebo group
that did not complete the study for unspecified reasons.
The results of the Leach, Morris et al. study were based on treatment of the amoxicillin
group for 5.7 months and the placebo group for 5.2 months. The outcome measured was whether
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there was any residual TM perforation present at the end of the therapy (see table 2 below). 12%
of those patients in the amoxicillin group and 27% of patients in the placebo group showed TM
perforations at the end of therapy. The RBI was –58%, the ABI was –16% and the NNT was –7
which signifies that for every seven patients treated with amoxicillin, there was one fewer patient
with a perforated TM at the end of therapy than in the placebo group. The 95% confidence
interval was 16 [-31, -1] (see table 3 below).
In the Couzos, Lea et al. study the treatment was for nine days and the clinical outcome
measured was a decrement (either one or two-step) in TM perforation size at the end of the study
(table 2). In the topical ciprofloxacin (experimental) group 26% of participants had a one or twostep decrement in TM perforation size as opposed to 23% in the topical FGD (control) group.
The RBI was 13%, the ABI was 3% and the NNT was 32 meaning that for every 32 patients
treated with topical ciprofloxacin, there is one more patient with a decrease in the size in the TM
perforation than in the topical FGD group. No confidence interval was reported (table 3) but the
reported p-value was 0.21 meaning the data is not statistically significant.
The Leach, Wood et al. trial studied the experimental and control treatments for six to
eight weeks with the measured clinical outcome as any remaining TM perforation at the end of
therapy (table 2). In the topical ciprofloxacin (experimental) study group, 98% had TM
perforation remaining at the end of therapy as opposed to 100% in the topical FGD (control)
group. The RBI was –2% the ABI was –2% and the NNT was -50 signifying that for every 50
patients treated with topical ciprofloxacin, one fewer patient had failure of the TM perforation to
heal after treatment than those patients treated with FGD. The 95% confidence interval was
reported as 2 [-6 to 2] (table 3).
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Table 2: Details of study samples, treatment duration and clinical outcomes measured
Study
Leach, A. J., Morris,
P. S. et al. (2008).

No. of pts in data analysis
103

Mean treatment duration
Amoxicillin 5.7 months
Placebo 5.2 months

Outcome measured
Any remaining TM
perforation at end of therapy

Couzos, S., T, Lea,
T. et al. (2003)

111

9 days

One or two step decrement in
TM perforation size

Leach, A., Wood, Y.
et. al. (2008)

97

6-8 weeks

Failure to heal perforation

Table 3: Tympanic membrane perforation at end of treatment period
Study
Leach, A. J., Morris, P.
S. et al. (2008)
Couzos, S., Lea, T. et
al. (2003)
Leach, A., Wood, Y. et.
al. (2008)

CER
Placebo
27%
FGD 23%

EER
Amox
12%
Cipro 26%

RBI
-58%

ABI
-16%

NNT
-7

13%

3%

32

FGD
100%

Cipro 98%

-2%

-2%

-50

CI or p-value
CI: 16 [-31, -1]
P-value: not reported
CI: not reported
P-value: 0.21
CI: 2 [-6 to 2]
P-value: not reported

The Leach, Morris et al. trial performed no discussion of patient compliance or treatment
adherence. The study does report that none of its participants were withdrawn due to “direct”
adverse reactions of the given medication though one child in the amoxicillin group and two in
the placebo group for withdrawn for continued CSOM despite treatment (see table 4 below).
No issues with patient compliance of ototopical treatment whether experimental or
control were detailed in the Couzos, Lea et al. study. Child guardians of the study participants
performed half of the study treatments while study workers performed the other half of the
treatments possibly reducing the chance of treatment noncompliance that may have been seen
had the child guardian been the sole treatment administrator. The study reports 21 “minor”
adverse reactions of the treatment stating 14 children noticed a bitter taste when given the
ototopical drops, five complained or ear pain and three of dizziness (table 4).
In the study discussion, Leach, Wood et al. make reference to the idea that there is room
for improvement in treatment adherence in the studied population but does not give specific
statistical data regarding adherence difficulties found in the study. Also, the report states that out
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of the twice daily ototopical treatments, study health workers supervised the morning dose and
family members administered the evening dose. It is possible that morning supervision of
treatment is likely to have increased overall treatment compliance. The study also mentions that
although ototoxicity was not directly measured in the study, there was no difference in hearing
loss between the FGD and ciprofloxacin groups at the end of the study period (table 4).
Table 4: Adverse outcomes of studies
Study

Ototoxicity

Ear pain

Dizziness

Bitter taste

Unresolved CSOM

Couzos, S., Lea, T. et al.
(2003)

None

5%

3%

14%

No mention

Leach, A. J., Morris, P. S. et
al. (2008)
Leach, A., Wood, Y. et al.
(2008)

No mention

No mention

No mention

No mention

3%

None

No mention

No mention

No mention

No mention

Discussion
The studies by Couzos, Lea et al. and Leach, Wood et al. demonstrate no significant
change in TM perforation size before or after the study period with either topical FGD or
ciprofloxacin treatment. The confidence interval for the Leach, Wood et al. study is narrow
meaning the authors can be confident that the results of their data are valid. Although no
confidence interval was reported for the study by Couzos, Lea et al., the p-value for the
measured outcome was 0.21 meaning that the results are not statistically significant and more
likely due to chance. The study by Leach, Morris et al. notes significant prevention in TM
perforation with use of long-term amoxicillin. The confidence interval for the Leach, Morris et
al. study is moderately wide signifying more studies should be done before definitively stating
the effectiveness of amoxicillin in TM perforation prevention.
One of the potential drawbacks of the aminoglycoside containing ototopical FGD is that
it is known to be ototoxic. The studies with FGD and ciprofloxacin treatment state there were no
participants with ototoxicity as a result of FGD use at the follow-up period, which was several
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months after the study end. Thus, the risk of ototoxicity with aminoglycoside use may be less
common than previously thought so a longer follow-up period regarding ototoxicity is warranted.
Amoxicillin is one of the most commonly used pediatric drugs, is generally safe and is
available in an oral form. A clinician must be aware of the potential amoxicillin side effects
especially when using the drug long-term as suggested in this review. Examples of some side
effects are stomach upset, vomiting, diarrhea, rash, tooth discoloration, hepatic dysfunction and
hematologic dysfunction such as hemolytic anemia. Amoxicillin must be dose adjusted in
pediatric renal patients. It is contraindicated in patients taking other drugs such as probenecid or
methotrexate. It is considered to be in pregnancy category B and is found in breast milk.
The rural location of the studies and lower socioeconomic status of the Aboriginal
population in Australia is a limitation to the three studies. As stated in several of the studies,
adherence to specific medication regimens for the amount of time specified may have been
difficult in this particular population. Consistency and strict adherence to the medication regimen
can be difficult especially in families with several child caretakers, caretakers that work or in
lower income families prone to psychosocial issues affecting proper medication administration.
Another potential limitation of the systematic review as a whole was the variation
between the different studies in the initial TM perforation size prior to treatment. The study by
Couzos, Lea et al. states that the study participants had varying sizes of TM perforations at the
beginning of the study trial though there was no association between the clinical cure and the
initial size of the TM perforation. In the report by Leach, Morris et al. the majority of study
participants had only OME so the lack of initial TM perforation had no effect on TM perforation
healing. In the study by Leach, Wood et al. the TM perforation at the end of treatment was
measured as a percentage of the initial TM perforation minimizing the chance that initial
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perforation size could have affected the study outcome. As described above there were a variety
of initial TM states between the three studies even though the initial condition of the TM had no
effect on the ending condition. Future systematic reviews on antibiotic therapy for TM
perforation should have more consistency in the initial state of the TM so as to minimize
unknown outside factors potentially affecting study data.
Conclusion
A thorough review of the articles by Leach, Morris et al. (2008), Couzos, Lea et al.
(2003) and Leach, Wood et al. (2008) demonstrates that neither ototopical FGD nor
ciprofloxacin are effective in healing TM perforation though they were found to be safe.
Systemic amoxicillin does appear to be safe and effective when compared to placebo in
preventing TM perforation. It must be noted that the conclusion of amoxicillin’s effectiveness is
based upon a review of one research article with a moderately wide confidence interval. Another
systematic review containing two or more studies of amoxicillin in treating TM perforation is
more ideal in confirming or disproving its effectiveness.
The data obtained from this systematic review should be used as a guideline for future
studies looking at treatment of the various forms of OM seen in high-risk US children such as
those living in urban settings or low-income communities. As of December 2010, no systematic
reviews, to the knowledge of the author, have been performed in the US looking specifically at
treatment of OME or CSOM in high-risk or lower income children. Studies looking at treatment
of AOM have been conducted in higher income countries and a systematic review looking at
long-term treatment in prevention of acute and chronic suppurative otitis media has been
performed in higher-risk populations from various countries, but none specifically in the US
alone. The data demonstrated in this systematic review is applicable to high-risk populations in
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the US though there may be genetic, cultural and other differences between the Aboriginal
population and high-risk populations in the US warranting US specific studies.
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